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Abstract
Context: Glial cells missing 2 (GCM2), a zinc finger-transcription factor, is essentially
required for the development of the parathyroid glands.
Objective: We sought to identify whether the epigenetic alterations in GCM2 transcription
are involved in the pathogenesis of sporadic parathyroid adenoma. In addition, we
examined the association between promoter methylation and histone modifications
with disease indices.
Methods: Messenger RNA (mRNA) and protein expression of GCM2 were analyzed
by reverse transcriptase–quantitative polymerase chain reaction (RT-qPCR) and
immunohistochemistry in 33 adenomatous and 10 control parathyroid tissues. DNA
methylation and histone methylation/acetylation of the GCM2 promoter were measured
by bisulfite sequencing and chromatin immunoprecipitation–qPCR. Additionally, we
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Primary hyperparathyroidism (PHPT) occurs because of
the enlargement of one or more parathyroid glands, which
causes overproduction of parathyroid hormone (PTH)
(1). However, there is limited literature on the molecular
mechanism involved in parathyroid tumorigenesis. Glial
cells missing 2 (GCM2) is a master regulator required for
the development of parathyroid glands in mammals (2-4).
In GCM2-knockout mice, missing parathyroid glands develop hypocalcemia and hyperphosphatemia, as observed
in hypoparathyroidism (5). Since parathyroid glands are
not formed in GCM2-knockout mice, parathyroid precursor cells undergo apoptosis and die soon after birth (3,
6).
GCM2 is a zinc-type nuclear transcription factor containing a DNA binding domain at the N-terminus that
binds to the consensus motif 5′-ATGCGGGT-3′ (2, 7-9).
GCM2 is known to be expressed in parathyroid glands;
however ,the downstream targets of GCM2 and its deregulation in parathyroid adenomas have not been explored
(10). Inactivating mutations in the GCM2 gene can lead to
decreased secretion of PTH, resulting in congenital isolated
hypoparathyroidism (5, 11, 12).
In silico studies have shown that transcription factors,
that is, GCM2-functional binding elements, are present in
the calcium-sensing receptor (CASR) promoter 1 (–451 to
–441 bp relative to the transcription start site [TSS]) and
promoter 2 (–166 to –156 bp relative to the TSS), and are
able to transactivate CASR expression (13-15). Previous
studies reported decreased GCM2 expression both in vivo
in mice and in human parathyroid cultured cells treated
with GCM2 small interfering RNA that is associated with

reduction of the CaSR gene, a marker of differentiation for
parathyroid cells (16).
It has also been demonstrated that GCM2 interacts with
other transcription factors such as GATA binding protein
3 (GATA3) and musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB), and determines PTH expression
in cultured cells (8). Nucleotide sequence analysis revealed
binding sites for the transcription factors GATA3 (–55 to
–18 relative to the TSS) and paired box 1 (PAX1; +8 to
+17 relative to the TSS), on the promoter region of GCM2,
and GATA3 and PAX1 both are essential for parathyroid gland development during embryogenesis (17, 18).
However, little is known about the molecular mechanisms
involved in the transcriptional regulation of GCM2 and
in the downstream activities of GCM2 protein in normal
parathyroid tissue or why there is decreased GCM2 expression in cultured parathyroid cells isolated from chronic
kidney disease patients (14). Hence, we asked whether epigenetic modifications such as DNA methylation and histone posttranslational changes regulate GCM2 expression.
DNA methylation is mediated by DNA methyltransferases
(DNMTs) that modify cytosine-guanine dinucleotide (CpG)
sites, which may result in gene silencing (19). Histone modifications are posttranslational changes to DNA packaging
histone proteins that promote chromatin remodeling and
changes in gene expression. Methylation and acetylation
are the 2 well-characterized histone modifications associated with transcriptional repression and activation of many
other target genes. Because of the reversibility of epigenetic modifications, pharmacological agents like 5-aza-2′deoxycytidine (DAC) and BRD4770 are used to reverse this
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investigated the role of epigenetic modifications on GCM2 and DNA methyltransferase 1
(DNMT1) expression in parathyroid (PTH)-C1 cells by treating with 5-aza-2′-deoxycytidine
(DAC) and BRD4770 and assessed for GCM2 mRNA and DNMT1 protein levels.
Results: mRNA and protein expression of GCM2 were lower in sporadic adenomatous
than in control parathyroid tissues. This reduction correlated with hypermethylation
(P < .001) and higher H3K9me3 levels in the GCM2 promoter (P < .04) in adenomas. In
PTH-C1 cells, DAC treatment resulted in increased GCM2 transcription and decreased
DNMT1 protein expression, while cells treated with the BRD4770 showed reduced
H3K9me3 levels but a nonsignificant change in GCM2 transcription.
Conclusion: These findings suggest the concurrent association of promoter
hypermethylation and higher H3K9me3 with the repression of GCM2 expression in
parathyroid adenomas. Treatment with DAC restored GCM2 expression in PTH-C1 cells.
Our results showed a possible epigenetic landscape in the tumorigenesis of parathyroid
adenoma and also that DAC may be a promising avenue of research for parathyroid
adenoma therapeutics.
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Materials and Methods
Baseline Participant Characteristics
Participants were enrolled, sampled, and analyzed after
giving written informed consent. This study was approved
by the institutional ethics committee at the Post Graduate
Institute of Medical Education and Research, Chandigarh,
India. Participants were diagnosed with PHPT if they
presented with elevated plasma PTH and hypercalcemia.
A family history suggestive of genetic forms of PHPT such
as multiple endocrine neoplasia 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), multiple endocrine neoplasia type 4 (MEN4), familial hypocalciuric hypercalcemia
syndrome, neonatal severe hyperparathyroidism, HPT-jaw
tumor, and familial isolated PHPT were excluded from the
study. The differential diagnosis can also be assisted by
clinical features, and those related to genetic PHPT were
excluded by appropriate clinical examination such as acromegaly, galactorrhea, neurofibromatosis, thyroid cancer
surgery, jaw tumor, and appropriate hormonal measurements (serum prolactin and insulin-like growth factor 1).
However, gene testing of MEN1 is the desired diagnostic
criterion because it identifies germline mutations even
without apparent family history of PHPT.
In total, we collected 40 tissue samples from PHPT patients with histologically confirmed parathyroid adenoma
(PA) and, from 10 patients, normal parathyroid (control)

during required thyroid surgeries. The tissue samples were
routinely fixed in 10% buffered formalin and processed for
hematoxylin and eosin stain in the department of histopathology of the institution. The slides were examined
to confirm the diagnosis either as adenoma or as normal
parathyroid tissue by an experienced endocrine pathologist
(U.N.S.).
For each sample, relevant clinical details were recorded
and biochemical measurements such as serum calcium (reference range [RR], 8.2-10.2 mg/dL), serum phosphorus
(RR, 2.7-4.5 mg/dL), serum creatinine (RR, 0.50-1.20 mg/
dL), serum albumin (RR, 3.5-5.5 g/dL), and alkaline phosphatase (RR, 40-129 U/L) were measured by an Olympus
autoanalyzer, and the serum calcium level was adjusted with
the serum albumin level. Plasma intact PTH (iPTH; RR,
15-65pg/mL) and 25-hydroxyvitamin D (RR, 11.1-42.9 ng/
mL) were measured using immunochemiluminescence
(ELECSYS-2010; Roche Diagnostics).

Multiple endocrine neoplasia 1 (MEN1) Screening
of Study Participants and In Silico Analysis of the
Pathogenic Effect of MEN1 variants
MEN1 mutation screening was performed for all study
participants from the genomic DNA samples. DNA was
isolated from the patient’s blood using a Qiagen DNA isolation kit and subjected to polymerase chain reaction (PCR)
amplification of all coding exons of the MEN1 gene. The
MEN1 mutations were identified by Sanger sequencing.
Post sequencing, the chromatograms were visualized and
analyzed using the CodonCode Aligner. Patients with
a MEN1 variation were further studied; each variation
was analyzed in silico for any possible benign or pathogenic effect using the MutPred bioinformatics tool (http://
mutpred.mutdb.org/). Only patients with no MEN1 mutation (n = 33) were included in this study to rule out a genetic contribution to disease pathology.

Analysis of Glial Cells Missing 2 and DNA
Methyltransferase 1 Gene Expression
Total RNA was isolated from each parathyroid adenoma and normal parathyroid tissue and reverse transcribed as described previously (24). GCM2 and DNMT1
mRNA levels were quantified by reverse transcriptase–
quantitative PCR (RT-qPCR) on an ABI StepOnePlus
Real-Time PCR System (Applied Biosystems) using 18s
ribosomal RNA as a housekeeping gene for normalization and specific primers: GCM2 forward primer
5′AAGGCATGCCCTAACTGTCA-3′ and GCM2 reverse
primer 5′ATGAACTCCCTTGGCCTGAA-3′; DNMT1 forward primer 5′TACCTGGACGACCCTGACCTC-3′ and
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process, making them perfect targets for prevention and
therapy. The potent and specific DNA methylation inhibitor
is DAC, a deoxyribose analogue of nucleoside that is converted to deoxynucleotide triphosphate and is then incorporated in place of cytosine into replicating DNA (20). DAC
is used to inhibit DNA methylation in tumor cells and helps
to increase the transcription of CASR in colon cancer (21,
22). The formal name of BRD4770 is 2-(benzoylamino)1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylic acid,
and it is used as a histone methyltransferase. Using specific
concentrations of BRD4770 will decrease demethylation
and trimethylation of lysines on histone 3. A previous
study on pancreatic cancer showed the expected effects of
BRD770, as it stops the proliferation of pancreatic cancer
cells without resulting in apoptosis (23).
Accordingly, in the present study we explored whether
DNA methylation and histone modifications affect the
regulation of GCM2 and promote parathyroid tumorigenesis. In addition, we explored the mechanism of epigenetic control of GCM2 by using DNA and histone
methyltransferase–inhibiting drugs in a rat cell line model
of parathyroid adenoma, and assessed the effects on GCM2
mRNA expression.
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Immunohistochemistry
The paraffin-embedded parathyroid adenoma and
normal parathyroid tissue blocks were retrieved from
the Department of Histopathology and 4- to 5-µ sections
were cut for immunohistochemistry (IHC). The IHC
protocol was performed as described previously (26).
Slides were graded semiquantitatively based on the
percentage of positive cells and staining intensity by
an endocrine pathologist (U.N.S.) for GCM2 (Abcam,
catalog No. ab201170, RRID:AB_2891136 [27]) protein
expression. Nuclear staining for GCM2 was regarded as
positive. Approximately 200 cells were counted in 6 different regions for each section under 40× magnification.
The staining intensity for the parathyroid adenoma and
normal parathyroid samples was assessed and graded
semiquantitatively: weakly positive (+; < 40%), moderately positive (++; 40%-60%), and strongly positive
(+++; > 60%) (24).

Bisulfite-Specific Polymerase Chain Reaction and
Sequencing
Genomic DNA from parathyroid adenoma and normal
parathyroid tissues were isolated and bisulfite-converted by
using the EZ DNA Methylation-Gold Kit (Zymo Research
Corp) as previously described (25).
For bisulfite-specific PCR, bisulfite-converted DNA
was amplified by using specific primer sets for GCM2:
forward primer 5′-TTTGGGTAATAGAGTGAGATAA
AAA-3′ and reverse primer 5′-AAAAACTAAAAACAAT
AATTATAAACCC-3′. Primers were used to amplify the
365-bp sequence containing 17 CpG sites located at nucleotides (nts) –300 to +240 relative to the GCM2 TSS.
PCR reaction was carried out using EpiTaq polymerase
enzyme (Takara). Amplified PCR products were separated by electrophoresis on 2% agarose gels and analyzed
by bisulfite sequencing (ABI 3730 XL DNA Analyzer;
Thermo Fisher Scientific). The sequencing data were
evaluated with the online software Bisulfite sequencing
and DNA Methylation analysis (BISMA) (25). A methylation density of greater than 10% was considered methylated for the specific gene examined (28).

Chromatin Immunoprecipitation of H3K9me3,
H3K27me3, and H3K9ac
Levels of H3K9m3 (Abcam, catalog No. ab8898,
RRID:AB_306848 [29]), H3K27me3 (Abcam, catalog
No. ab6002, RRID:AB_305237 [30]), and H3K9ac (Cell
Signaling Technology, catalog No. 9649, RRID:AB_823528
[31]) on the GCM2 promoter region were quantified by
chromatin immunoprecipitation (ChIP)-qPCR assay.
Twenty-three parathyroid adenoma samples were processed for each ChIP-qPCR assay, and the experiment
was performed as described previously (22, 32). In brief,
25 to 30 mg of homogenized frozen tissue was fixed with
1% paraformaldehyde at room temperature for 10 minutes, stopped with 0.125-M glycine, and lysed for 10 minutes on ice. The lysate was digested in 1-mL lysis buffer
using a tissue homogenizer (NaCl 150 mM, Tris HCl
[pH 7.5] 25 mM, EDTA 5 mM, Triton X 100 1%, sodium dodecyl sulfate 0.1%, sodium deoxycholate 0.5%,
phenylmethylsulfonyl fluoride 1 mM, and sodium butyrate
10 mM) 1X PIC followed by resuspension in lysis buffer
for sonication 15 cycles (30 seconds on and 30 seconds
off) using a Diagenode sonicator. Cross-linked DNA was
immunoprecipitated with nonspecific immunoglobulin G
(IgG) antibodies (45% of total supernatant [Abcam, catalog
No. ab171870, RRID:AB_2687657] [33]) for isotype control and immunoprecipitation with anti-H3K9m3, antiH3K27me3, and anti-H3K9ac antibodies (45% of total
supernatant) was performed overnight at 4 °C. The next
day, samples were pulled down with protein A/G beads,
washed, reverse cross-linked, and ChIP-DNA was extracted
with phenol-chloroform isoamyl alcohol as described previously. For ChIP-qPCR assay, primers were designed by using
primer blast provided by National Center for Biotechnology
Information and sequences used were GCM2 forward
primer 5′-TGTGCTCCTACGGGATGCAG-3′ and GCM2
reverse primer 5′-CCCTCCTTCGGATGGACAGC-3′.
qPCR with ChIP primers was carried out and performed
in duplicate, and levels of H3K9me3, H3K27me3, and
H3K9ac were calculated by the fold enrichment method
relative to the nonspecific antibody and normalized to the
input DNA.
Parathyroid-C1 cell line
Because a human parathyroid cell line is not available, the
parathyroid-C1 (PTH-C1) cell line, which was established
from rat parathyroid tissue, was used for in vitro treatment
assays (34). The PTH-C1 cells have an epithelial morphology and exhibit parathyroid functional features (34). The
cells were cultured in 25 cm2 or 75 cm2 tissue culture flasks
supplemented with nutrient mixture F-12 Ham Coon’s
modification (Sigma-Aldrich) containing 10% fetal bovine
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DNMT1 reverse primer 5′-CGTTGGCATCAAAGATGG
ACA-3′. RT-qPCR reaction conditions were similar to those
described in our previous article (25). Experiments were performed in duplicate with 2 nontemplate controls as a negative control. The 2–ΔΔCT method was used to quantify the
relative expression of GCM2 and DNMT1 as a fold change.
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serum (Gibco, Thermo Fisher Scientific), and 100-U/mL
penicillin/streptomycin (Gibco, Thermo Fisher Scientific)
and then incubated at 37 °C in a 5% CO2 incubator.

Impact of 5-aza-2′-deoxycytidine treatment on glial cells
missing 2 expression in parathyroid-C1
To study the impact of DAC on the expression of GCM2
in PTH-C1 cells by RT-qPCR, cells were treated with
10-µM DAC for 72 hours (the fresh drug was changed
every 24 hours). Total RNA was isolated from treated and
untreated PTH-C1 cells, reverse transcribed, and GCM2
mRNA expression was assessed by RT-qPCR as described
earlier for tissue samples (25). In treatment experiments,
rat-specific GCM2 primers were used: forward primer
5′-TGCCTCAGGAACCAGCTCACT-3′ and reverse primer
5′-AGGTGGCGCTGAGCTTTCTTC-3′.
Experiments
were performed in triplicate with 2 nontemplate samples
as a negative control. Data were normalized using β-actin
(forward primer 5’CCCATCTATGAGGGTTACGC-3′ and
reverse primer 5′-TTTAATGTCACGCACGATTTC -3′) as
a housekeeping gene and relative expression by fold change
was calculated using 2–ΔΔCT value.
Impact of BRD4770 treatment on glial cells missing 2
expression in parathyroid-C1
After treatment with 5-µM BRD4770 in PTH-C1
cells for 48 hours, H3K9me3 levels assessed by ChIPqPCR and mRNA expression of GCM2 were quantified by RT-qPCR. ChIP-qPCR assay was performed on
ChIP-DNA isolated from treated and untreated PTHC1 cells. Rat-specific GCM2 primers (forward primer
5′-GGAGCCTGAGGTAATGGGCT-3′ and reverse primer

5′-ATTAGAGCCCCGAGCCAAGG-3′) were used in the
qPCR. Finally, ChIP-qPCR was performed, and analysis
was carried out as described earlier for human parathyroid
tissue samples.
Immunofluorescence staining of DNA methyltransferase 1
in parathyroid-C1 cells
After treatment with DAC, PTH-C1 cells were grown
on 8-well glass-chambered slides and fixed with 4%
paraformaldehyde in 1X PBS for 20 minutes, then washed
extensively with 1X PBS. Cells were permeabilized with
0.2% Triton-X in 1X PBS for 20 minutes and blocked with
2% bovine serum albumin in PBS for 1 hour. Primary antibodies for proteins of interest (DNMT1; Abcam, catalog
No. ab188453, RRID:AB_2877711 [35]) were diluted
in 2% bovine serum albumin and applied to the cells.
Slides were incubated for 4 hours at room temperature.
After washing with 1X PBS, a secondary antibody-labeled
fluorochrome (1:500) was applied to the cells for 1 hour at
room temperature in the dark. The cells were washed once
for 5 minutes with 1X PBS. Nuclear staining and mounting
were performed with Anti Fade Gold reagent (Thermo
Fisher Scientific). Whole-slide images were acquired using
an EVOS microscope with appropriate fluorescent labels.
Statistical analysis
Graph Pad Prism version 6.0 was used to analyze the data.
qPCR data are expressed as mean ± SD and ChIP-qPCR
data expressed as mean ± SEM. In vitro data represent
3 independent trials and are shown as mean with SEM.
A P value of less than .05 was considered statistically significant. Mann-Whitney, chi-square, and t tests were used
as appropriate to compare the differences in study data between the control and adenoma samples. The Pearson correlation test was used to examine the relationship among
various continuous variables.

Results
Characteristics of Primary Hyperparathyroidism
Patients
The mean age of the patients with confirmed parathyroid
adenoma was 43 ± 13.5 years (range, 18-65 years) with a
female to male ratio of 3:1 (31 women and 9 men). The
mean age of the patients with normal parathyroid function
who had undergone required surgery for benign thyroid disease was 43 ± 13.3 years (range, 25-61 years; 7 women and
3 men). The presence of bone pains, weakness, and fatigue,
kidney stones, gallstone disease, fractures, pancreatitis, and
vitamin D deficiency (25-hydroxyvitamin D level < 20 ng/
mL) at the time of presentation was categorized as
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In vitro treatments and 3-(4, 5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide assay
A stock solution of DAC or BRD4770 (Sigma-Aldrich)
was made in vehicle and diluted to appropriate concentrations for treatment. Cells treated with vehicle control were
taken as controls. Approximately 1 × 104 cells were seeded
per well in a 96-well plate and then subsequently treated
with different concentrations of DAC for 72 hours and
BRD4700 for 48 hours alone, respectively. At the end of
the treatments, 100 µL of 3-(4, 5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) reagent was added
to each well from a 5-mg/mL stock in phosphate-buffered
saline (PBS). The 96-well plates were incubated for 3 hours
at 37 °C in the dark. The supernatant was taken out and
formazan crystals were dissolved in 100-µL dimethyl
sulfoxide at 37 °C for 10 minutes with gentle agitation.
Absorbance from the plates was read at 570 nm and reference was read at 620 nm with an enzyme-linked immunosorbent assay reader.
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Glial Cells Missing 2 Promoter Hypermethylation
in Sporadic Parathyroid Adenomas

DNA Methyltransferase 1 Expression in
Parathyroid Adenomas

Bisulfite-converted DNA sequence analysis showed that
17 CpG sites (nt –300 to +240 relative to the TSS) located

Because we observed such a high level of methylation
in the GCM2 promoter in parathyroid adenomas, we

Transcriptional Pattern of Glial Cells Missing 2 in
Sporadic Parathyroid Adenomas

Figure 1. Glial cells missing (GCM2) messenger RNA (mRNA) and protein expression analysis in sporadic parathyroid adenoma (N = 33). a, Bar graph
representing relative mRNA expression of GCM2 in parathyroid adenoma compared to control parathyroid samples. b, Representative photomicrographs showing GCM2 protein levels in A, parathyroid tissue sections control, and B, C, and D, show intensity in parathyroid adenoma as 1+, 2+, and
3+, respectively. Images captured at 40× magnification, scale bar = 400 µm.
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RT-qPCR analysis showed GCM2 mRNA levels were
significantly lower in 29 (88%) of the 33 sporadic parathyroid adenomas relative to the control parathyroid samples, with a mean fold-change reduction of 0.25 ± 0.25
(P < .0001) (Fig. 1A). IHC analysis revealed nuclear
staining for GCM2 protein both in the adenomatous and
control parathyroid gland samples. In the control parathyroid samples, we observed 3+ intensity. In contrast,
in the parathyroid adenomatous samples, we observed
1+ intensity in 16 of 33 (48%), 2+ intensity in 14 of 33
(42%), and 3+ intensity in 3 of 33 (9%) (Fig. 1B). The
mean proportion of GCM2-positive cells was 44 ± 22%
in sporadic parathyroid adenomas and 77.8 ± 3.4% in the
control parathyroid samples. GCM2 protein expression
was significantly reduced in the parathyroid adenomas
relative to the control parathyroid samples (P < .0001).

upstream of the GCM2 promoter (Fig. 2A) had high levels
of methylation in 57.5% (n = 19) of the parathyroid adenomas with a mean methylation density of 20.7 ± 6%
(range, 11.1%-33.3%). While 14 parathyroid adenomas
had a mean methylation density of less than 10%, 3 parathyroid adenomas did not show methylation at any CpG
sites in the region of the GCM2 promoter. Normal control parathyroid samples showed complete methylation at
none of the 17 CpG sites, except for a single sample that
showed an average of 6.7% methylation. Representative
unmethylated and methylated CpG sites in the GCM2 promoter region are shown in Fig. 2B. The promoter region
of GCM2 in parathyroid adenoma was highly methylated,
showing complete methylation at 13 of 17 CpG sites. Also
notable in the parathyroid adenomas, the eighth CpG site,
which is a putative GATA3 binding site (nt –55 to –18 relative to +1 TSS), showed an average methylation of 56.4%,
and the twelfth CpG site, a PAX1 binding site (nt +8 to +17
relative to +1 TSS), showed only 3.4% average methylation (Fig. 2C). Correlation analysis revealed a significant
negative association between GCM2 mRNA expression
and the level of methylation in sporadic parathyroid adenomas (r = –0.52; P < .001) (Fig. 2D). Thus, the reduced
expression of GCM2 in parathyroid adenoma tissues was
the effect of the methylation.

symptomatic PHPT. All the patients had hypercalcemia
,with mean serum calcium of 12.0 ± 1.0 (RR, 10.5-14.5 mg/
dL), elevated median iPTH level of 558 pg/mL (first interquartile range [IQR]-third IQR), and median parathyroid
adenoma weight was 2 g (first IQR-third IQR) (22).
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next examined the gene expression of the maintenance
methyltransferase DNMT1. We found that DNMT1
mRNA levels were significantly upregulated in sporadic parathyroid adenomas, with a mean fold change of
5.1 ± 3.7 (P < .0006) compared with the control parathyroid samples (Fig. 3). We found a significantly positive
association between DNMT1 mRNA levels and GCM2
promoter hypermethylation (r = 0.39; P < .03) in sporadic
parathyroid adenomas. Further, we observed that DNMT1
mRNA expression was positively associated with tumor
weight (r = 0.40; P < .03), although it was not associated
with any other biochemical parameters of parathyroid
adenomas.

H3K9me3, H3K27me3, and H3K9ac Modifications
in Sporadic Parathyroid Adenomas
Next, we investigated levels of posttranslational methylation and acetylation on histone 3 within the GCM2 promoter in adenomatous and control parathyroid tissues

using 23 adenomas and 10 control parathyroid samples.
ChIP-qPCR analysis revealed higher H3K9me3 levels
relative to IgG in the GCM2 promoter in parathyroid adenomas compared to control parathyroid, with a mean
fold increase of 7.67 ± 3.08 in parathyroid adenoma and
0.52 ± 0.16 in control parathyroid samples relative to IgG.
Levels of H3K27me3 relative to IgG were high in 19 of
the 23 (83%) parathyroid adenomas with an overall mean
fold increase of 31.2 ± 22.4, whereas the mean increase
was only 1.15 ± 0.23 in control parathyroid samples. Thus,
sporadic parathyroid adenomas exhibited 15-fold (P < .02)
and 26-fold (P < .004) higher levels of H3K9me3 and
H3K27me3, respectively, compared to control parathyroid
samples (Fig. 4A and 4B). In contrast, H3K9ac levels were
lower in parathyroid adenomas, with mean fold increases
of 3.03 ± 0.58 in 20 of the 23 (87%) and 14.6 ± 9.40 in the
control parathyroid samples relative to IgG (Fig. 4C). Thus,
the active histone marker H3K9ac was decreased by 5-fold
(P < .02) in sporadic parathyroid adenomas compared to
control parathyroid samples.
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Figure 2. Glial cells missing (GCM2) promoter methylation in sporadic parathyroid adenoma (N = 33). A, GCM2 promoter region selected for bisulfite
sequencing polymerase chain reaction showing putative GATA3 and PAX1 binding sites and the transcription start site (TSS). B, Representative
chromatograms showing methylated sites (blue arrow) in parathyroid adenoma compared to control parathyroid. C, Tabular representation of 17
cytosine-guanine dinucleotide (CpG) sites at GCM2 promoter showing average percentage methylation at each CpG site. D, Scatter plot showing the
negative association between gene expression of GCM2 and DNA promoter methylation in sporadic parathyroid adenoma cases (N = 33).
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5-Aza 2′-deoxycytidine and BRD4770 cytotoxicity
detection using the 3-(4, 5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide assay
To detect the cytotoxicity of DAC and BRD4770, we performed the MTT assay. As shown in Fig. 5, there was no
significant difference between the experimental group

and negative control. We conclude that 10-μM DAC and
5-μM BRD4770 produced no cytotoxicity in PTH-C1 cells,
respectively.

Inhibition of DNA Methyltransferase 1 With 5-Aza
2′-Deoxycytidine Results in Higher Glial Cells
Missing 2 Transcription in Parathyroid-C1 cells
To test whether inhibition of DNMT1 would result in increased GCM2 transcription by putatively relieving epigenetic inhibition, we treated the transformed rat parathyroid
cell line, PTH-C1, with DAC, and measured the mRNA
levels of GCM2 by RT-qPCR. In PTH-C1 cells, we observed
that the expression of GCM2 was significantly increased
(P < .001) (Fig. 6A) after treatment with 10-μM DAC for
72 hours relative to untreated cells. Immunofluorescence
microscopy revealed reduced protein levels of DNMT1
after treatment with 10-μM DAC for 72 hours in PTH-C1
cells compared to untreated cells (Fig. 6B).

Histone Methylation (H3K9me3) and Glial Cells
Missing 2 Expression in Parathyroid-C1 cells in
response to BRD4770

Figure 3. Bar graph representing relative messenger RNA (mRNA) expression of DNA methyltransferase 1 (DNMT1) in parathyroid adenomas compared to control parathyroid samples.

Next, to show that treatment with the histone
methyltransferase inhibitor BRD4770 affects the H3K9me3
modification within the GCM2 promoter, a ChIP-qPCR
assay was performed to measure H3K9me3 levels. In ChIPqPCR analysis, we observed a decrease of H3K9me3 levels
in the GCM2 promoter region in BRD4770-treated PTHC1 cells compared to untreated cells (Fig. 7A). However, we
found a slight but not significant increase of GCM2 mRNA
in BRD4770-treated PTH-C1 cells relative to untreated
cells (Fig. 7B).

Figure 4. Chromatin immunoprecipitation–quantitative polymerase chain reaction for Glial cells missing (GCM2) promoter region in sporadic parathyroid adenomas. Quantification of fold enrichment in A, H3K9me3; B, H3K27me3; and C, H3K9ac (levels relative to nonspecific immunoglobulin G
as control and normalized with input DNA). Bars represent mean fold enrichment and SEM (n = 23).
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The Pearson correlation analysis between GCM2
mRNA expression and H3K9me3 methylation, a repressive modification associated with gene repression, showed
a significantly negative association in parathyroid adenomas (r = –0.49, P < .04). The other repressive modification, H3K27me3, was significantly associated with serum
calcium, whereas the activating modification, H3K9ac,
showed a significant inverse relationship with plasma iPTH
in parathyroid adenomas.
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Discussion
In the present study, we demonstrate that GCM2, a master
regulator for parathyroid gland development (36), is
hypermethylated in parathyroid adenomas and results
in downregulated expression of GCM2 mRNA. We also
found that H3K9me3 and H3K27me3 levels were higher,
and H3K9ac was lower, in adenomatous compared to control parathyroid samples. Furthermore, treatment with
DAC, a DNA methyltransferase inhibitor, can restore
GCM2 expression in PTH-C1 cells. To our knowledge, this
is the first study to fully describe the epigenetic landscape of
the GCM2 promoter in human parathyroid adenomas, and
the first to report that promoter DNA hypermethylation
contributes to the regulation of GCM2 in sporadic parathyroid adenomas.
We observed significantly reduced mRNA and protein
expression of GCM2 in sporadic parathyroid adenomas
relative to control parathyroid samples. These findings are
in agreement with previous reports that showed similar
underexpression of GCM2 in parathyroid tumors (14, 37).

One limitation of the present study is that the genetic
status of GCM2 was not analyzed in sporadic parathyroid
adenomas. Previous studies by Kebebew and colleagues in
2004 and Mannstadt et al in 2011 showed underexpression
or overexpression of the GCM2 gene in parathyroid adenomas, respectively (10, 38). Activating mutations might
account for the overexpression of the GCM2 gene. Another
study by Guan et al in 2016 that studied the genetic status
of the GCM2 identified the non–C-terminal conserved
inhibitory domain (CCID) variant in the Italian population; however, it did not appear in Asian/Indian population
(39). In a subset of families with familial isolated PHPT,
germline-activating mutations affecting the GCM2 CCID
variants were observed (39) and have never been found in
MEN1 or HPT-jaw tumor syndrome. Of note, Guan et al
in 2017 concluded that GCM2-activating variants were
seen in the sporadic PHPT patients who had multigland
involvement or persistent disease (40). However, Riccardi
and colleagues in a 2019 study reported that the known
GCM2-activating variants may not intend to develop a
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Figure 5. Cell viability was analyzed with 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay in parathyroid (PTH)-C1 cells
after using different concentrations of A, 5-aza 2′ deoxycytidine (DAC) for 72 hours. Data are shown as means of 3 experiments in triplicate (P < .78).
B and C, Representative bright-field images of control and DAC-treated PTH-C1 cells for 72 hours; and D, 2-(benzoylamino)-1-(3-phenylpropyl)-1Hbenzimidazole-5-carboxylic acid (BRD4770), for 48 hours. Data are shown as means of 3 experiments in triplicate (P < .40). E and F, Representative
bright-field images of control and BRD4770-treated PTH-C1 cells for 48 hours at 20×, scale bar = 200 μM.
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Figure 7. The effect of 2-(benzoylamino)-1-(3-phenylpropyl)-1H-benzimidazole-5-carboxylic acid (BRD4770) treatment in a parathyroid cancer cell
line (PTH-C1). PTH-C1 cells were treated with 5 µM of BRD4770 for 48 hours. A, Presence of H3K9me3 modification in the glial cells missing (GCM2)
promoter quantified by chromatin immunoprecipitation–quantitative polymerase chain reaction. After treatment with BRD4770, decreased in
trimethylation of H3K9 level was observed in the GCM2 promoter region. B, Expression of GCM2 messenger RNA (mRNA) relative to actin in the
PTH-C1 cell line before and after BRD4770 treatment. Results are shown as mean and SEM values, and P values were evaluated by t test from 3 independent experiments.

sporadic adenoma, though increased disease risk would be
expected in carriers of such variants compared with the
general population (41). But the exact mechanism of deregulated GCM2 expression in parathyroid tumorigenesis
is still undetermined.
Interestingly, Canaff et al in 2007 identified functional
GCM2-binding sites on CaSR promoters (promoter 1
and promoter 2); thus, there appears to be an association
between GCM2 and CaSR (14). Our recent study also
showed hypermethylation of a CpG site located within the
GCM2-binding region on the CaSR promoter 2 affected

CaSR expression in patients with sporadic parathyroid adenomas (22, 24, 37). Thus, the methylation analysis of a
specific CpG site might play a key determinant role in the
reduced gene expression. In the present study, the GCM2
promoter was hypermethylated with a significant inverse
relationship between GCM2 mRNA expression and promoter methylation. Previously, it has been reported that
loss of GCM2 expression in renal cell carcinoma is due
to genetic deletions and that tumor-specific methylation
correlates with survival (42). The GCM2 promoter contains putative GATA3 and PAX1-binding sites, and both
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Figure 6. The effect of 5-aza-2′-deoxycytidine (DAC) treatment in a parathyroid cancer cell line (PTH-C1). A, Expression of glial cells missing (GCM2)
messenger RNA (mRNA) relative to beta actin in PTH-C1 cells treated with 10 µM DAC vs untreated cells at 72 hours as determined by reverse transcriptase–quantitative polymerase chain reaction. The results are shown as mean and SEM values and P values were evaluated using t test from
3 independent experiments. B, Representative immunofluorescence staining of DNA methyltransferase 1 (DNMT1; red) in PTH-C1 cells (untreated
with DAC, upper panel; treated with DAC, bottom panel). Nuclei were stained with 4′, 6-diamidino-2-phenylindole (DAPI; blue). Images captured at
20× magnification. Scale bar = 200 µm.
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decreased RASSF1A expression in breast cancer (46). Thus,
we propose a possible role for H3K9me3 as a chief regulator in parathyroid tumorigenesis that should be investigated further.
We further examined the role of GCM2 promoter DNA
and histone methylation by using the epigenetic inhibition
drugs DAC and BRD4770 in the PTH-C1 cell line to observe
whether they might cause reactivation of silenced GCM2 in
PTH-C1 cell line. Several reports in colorectal cancer cell
lines such as HCT116, SW48, and SW480 have shown
that DAC treatment inhibits DNMT1 activity, causing
reexpression of genes such as clusterin, interleukin-23 receptor, transketolase-like 1, and tubulin α-3C (47). We saw
a reduction of DNMT1 protein in DAC-treated PTH-C1
cells and a concomitant significant increase in GCM2 gene
expression after DAC treatment. The restoration of GCM2
expression suggests that inhibition of DNMT1 is sufficient
and necessary to activate the GCM2 promoter. Previous
studies have reported that DAC has been recognized as a
therapeutic epigenetic-modifying drug and has been approved for the treatment of cancer (21, 47, 48).
In addition, we also further explored the role of
H3K9me3 in PTH-C1 cells, since increased H3K9me3
levels were observed in the GCM2 promoter in human
sporadic parathyroid adenomas. Thus, PTH-C1 cells treatment with BRD4770 resulted in lower H3K9me3 levels
in the GCM2 promoter as observed by ChIP-qPCR, but
changes in GCM2 transcription were not significantly different between treated and untreated cells, despite a trend
suggestive of increased expression. BRD4770 has shown
success in reducing H3K9me3 levels in pancreatic and liver
cancer cells without inducing apoptosis (23).
The data on PTH-C1 cells, while not significant, may indicate a promising topic for future, more detailed research
on the role of H3K9me3 histone modification in parathyroid disease.
Taken together, DNA hypermethylation and higher histone H3K9me3 levels in the GCM2 promoter in sporadic
parathyroid adenomas both suggest that epigenetic modifications play a key role in the transcriptional silencing of
GCM2, perhaps contributing to parathyroid tumorigenesis.
The limitations of this study, first, we did not determine
the genetic status of the GCM2 gene in sporadic parathyroid adenomas. Second, in vitro experiments were performed in the rat parathyroid cell line PTH-C1 (34). As
of yet, there is no human parathyroid cell line available
for ideal in vitro experiments; however, transformed rat
parathyroid cell lines may serve as an excellent model to
study potential therapeutics. Third, protein expression of
DNMT1 was not performed in parathyroid adenomas.
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are developmental transcription factors that regulate
GCM2 expression (6, 8). A noteworthy observation was
that the eighth (GATA3-binding site) and twelfth CpG
sites (PAX1-binding site) showed 57.5% methylation and
3.4% methylation, respectively, in sporadic parathyroid
adenoma. Similarly, others have reported that GATA3 acts
via GCM2 regulation in parathyroid adenomas, as the
GCM2 promoter is enriched with GATA3-binding motifs (6, 43). Another study reported that GATA3 interacts
with GCM2 and MAFB transcription factors resulting in
stimulation of PTH gene expression (8). Also, there is a
strong link between PAX1 and GCM2, as PAX1 also helps
to determine cell fate in the development of the parathyroid glands (17). Our results showed that GCM2 promoter
hypermethylation, as well as specific methylated CpG sites,
might lead to steric hindrance for transcription factor
(GATA3 and PAX1)-binding, causing decreased GCM2
expression. This observation is of key interest for future
investigations exploring predictive and prognostic biomarkers for sporadic parathyroid adenomas.
Our study showed significantly increased mRNA expression of DNMT1 in sporadic parathyroid adenomas
compared to control parathyroid samples. A previous
study on MEN showed DNA hypermethylation to be mediated by enhanced DNMT1 activity, thereby regulating
the transcriptional silencing of menin 1 (MEN1). In this
study, we found that DNMT1 expression was strongly associated with GCM2 promoter methylation patterns in
sporadic parathyroid adenomas, suggesting that reduced
expression of GCM2 may be due to DNMT1-mediated
methylation. Correlation analysis suggested a significant
association between DNMT1 mRNA expression and
tumor weight in sporadic parathyroid adenomas. Earlier
reports have suggested giant or large parathyroid tumor
size correlates well with the severity of the disease (44, 45).
This suggests that large tumor weight results in a more
pronounced clinical picture in sporadic PHPT patients,
with severe hypercalcemia and elevated iPTH levels.
Additionally, to understand the reason for reduced
GCM2 expression, histone modifications have been
studied. However, this is the first study to analyze histone
changes in the promoter region of GCM2 in parathyroid
adenoma, and we observed significantly higher H3K9me3
and H3K27me3 levels and lower H3K9ac levels. In a
similar manner, we observed a significant inverse relationship of promoter hypermethylation and H3K9me3 levels
with reduced GCM2 expression in sporadic parathyroid
adenomas, thus linking both with transcriptional silencing. This is in line with a previous study that reported an
interplay of histone modification and DNA methylation in
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